Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT)

References

• Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182:1177–1182.
   PubMed Web of Science ®Google Scholar
• Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health. 1990;80:331–333.
   PubMed Web of Science ®Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.
   PubMed Web of Science ®Google Scholar
• Bonkat G, Pickard R, Bartoletti R, et al. EAU Guidelines on Urological Infections; 2017 cited 2017 Apr 27. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Urological-Infections-v2.pdf.
   Google Scholar
• Nosseir SB, Lind LR, Winkler HA. Recurrent uncomplicated urinary tract infections in women: a review. J Womens Health (Larchmt). 2012;21:347–354.
   PubMed Web of Science ®Google Scholar
• Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon. 2003;49:71–82.
   PubMed Web of Science ®Google Scholar
• Kodner CM, Gupton T, Emily K. Recurrent urinary tract infections in women: diagnosis and management. Am Fam Physician. 2010;82:638–643.
   PubMed Web of Science ®Google Scholar
• Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616, e 48.
   Web of Science ®Google Scholar
• Glover M, Moreira CG, Sperandio V, et al. Recurrent urinary tract infections in healthy and nonpregnant women. Urol Sci. 2014;25:1–8.
   PubMedGoogle Scholar
• Stamey TA, Sexton CC. The role of vaginal colonization with Enterobacteriaceae in recurrent urinary infections. J Urol. 1975;2:214, e 7.
   Google Scholar
• Hooton TM, Roberts PL, Cox ME, et al. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013;369:1883–1891.
   PubMed Web of Science ®Google Scholar
• Eriksson I, Gustafson Y, Fagerstrom L, et al. Do urinary tract infections affect morale among very old women? Health Qual Life Outcomes. 2010;8:73–78.
   PubMed Web of Science ®Google Scholar
• Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151:1194–1205.
   PubMed Web of Science ®Google Scholar
• Abrahamian FM, Krishnadasan A, Mower WR, et al. The association of antimicrobial resistance with cure and quality of life among women with acute uncomplicated cystitis. Infection. 2011;39:507–514.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Verma S. Quality of life in women with urinary tract infections: is benign disease a misnomer? J Am Board Fam Pract. 2000;13:392–397.
   PubMedGoogle Scholar
• Ernst EJ, Ernst ME, Hoehns JD, et al. Women’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes. 2005;3:45.
   PubMedGoogle Scholar
• Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233.
   PubMed Web of Science ®Google Scholar
• Castelló T, Girona L, Gómez MR, et al. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord. 1996;34:592–593.
   PubMed Web of Science ®Google Scholar
• Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007;86:783–787.
   PubMed Web of Science ®Google Scholar
• Howell AB, Botto H, Combescure C, et al. Dosage effect on uropathogenic escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010;10:94.
   PubMed Web of Science ®Google Scholar
• Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD001321.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Betsi GI, Tokas T, et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs. 2006;66:1253–1261.
   PubMed Web of Science ®Google Scholar
• Baerheim A, Larsen E, Digranes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care. 1994;12:239–243.
   PubMedGoogle Scholar
• Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52:1212–1217.
   PubMed Web of Science ®Google Scholar
• Beerepoot MA, Geerlings SE, Van Haarst EP, et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190(6):1981–1989.
   PubMed Web of Science ®Google Scholar
• Perrotta C, Aznar M, Mejia R. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;2:CD005131.
   PubMed Web of Science ®Google Scholar
• Parfitt K, editor. Martindale: the complete drug reference. London: Pharmaceutical Press; 1999.
   Google Scholar
• Lee BS, Bhuta T, Simpson JM, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD003265.
   PubMed Web of Science ®Google Scholar
• Frey C, Obolensky W, Wyss H. Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int. 1986;41:444–446.
   PubMed Web of Science ®Google Scholar
• Schulman CC, Corbusier A, Michiels H, et al. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol. 1993;150:917–921.
   PubMed Web of Science ®Google Scholar
• Magasi P, Pánovics J, Illés A, et al. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994;26:137–140.
   PubMed Web of Science ®Google Scholar
• Chiavaroli C, Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs. 2006;20:141–149.
   PubMed Web of Science ®Google Scholar
• Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol. 1990;65:6–9.
   PubMedGoogle Scholar
• Bauer HW, Alloussi S, Egger G, et al. A long-term, multicenter, double-blind study of an escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47:542–548.
   PubMed Web of Science ®Google Scholar
• Popa G, Lauber D, Rothe H, et al. Recurrent postmenopausal urinary tract infections. Efficacy of oral immunotherapy with E. coli fractions. Munchener Medizinische Wochenschrift. 1996;138:713–716.
   Google Scholar
• Lettgen B. Prevention of recurrent urinary tract infections in female children: OM-89 Immunotherapy compared with nitrofurantoin prophylaxis in a randomized pilot study. Cur Ther Res. 1996;57:464–465.
   Web of Science ®Google Scholar
• Baerschi R, Balmer JA, Eduah SB, et al. Bacterial extract for the prevention of recurrent urinary tract infections in pregnant women: a pilot study. Int J Immunother. 2003;19:25–31.
   Google Scholar
• Hachen HJ. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol. 1990;143:759–762.
   PubMed Web of Science ®Google Scholar
• Bauer HW, Rahlfs VW, Lauener PA, et al. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19:451–456.
   PubMed Web of Science ®Google Scholar
• Naber KG, Cho YH, Matsumoto T, et al. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111–119.
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WJ, Balish E, et al. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J Urol. 1997;157(6):2049–2052.
   PubMed Web of Science ®Google Scholar
• Hopkins WJ, Elkahwaji J, Beierle LM, et al. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007;177(4):1349–1353.
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WJ, Elkahwaji JE, et al. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003;170(3):867–869.
   PubMed Web of Science ®Google Scholar
• Maruish ME. User’s manual for the SF-12v2 Health Survey. 3rd ed. Lincoln (RI): QualityMetric Inc; 2012.
   Google Scholar
• Averbeck MA. Madersbacher H: constipation and LUTS - how do they affect each other? Int Braz J Urol. 2011;37:16–28.
   PubMed Web of Science ®Google Scholar
• Klarskov OP. Training of patients with residual urine and/or recurrent urinary tract infections. Ugeskr Laeger. 1989;151:293–295.
   PubMedGoogle Scholar
• Wagenlehner F, Schmiemann G, Kranz J, et al. Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter bakterieller ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. S-3 Leitlinie der Arbeitsgemeinschaft Wissenschaftlicher Medizinischer Fachgesellschaften (AWMF) AWMF-Register-Nr 043/044. 2017.
   Google Scholar
• Devillé WLJM, Yzermans JC, van Duijn NP, et al. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol. 2004;4:4.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial consumption in Europe, 2010. Stockholm: ECDC; 2013 cited 2017 Jun. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-antibiotic-consumption-ESAC-report-2010-data.pdf
   Google Scholar
• Renard J, Ballarini S, Mascarenhas T, et al. Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther. 2015;4:125–135.
   Web of Science ®Google Scholar
• Eells SJ, Bharadwa K, McKinnell JA. Miller LG: recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis. 2014;58:147–160.
   PubMed Web of Science ®Google Scholar
• Colodner R, Kometiani I, Chazan B, et al. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection. 2008;36:41–45.
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Roberts PL, et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med. 2001;135:9–16.
   PubMed Web of Science ®Google Scholar